US7365095B2 - Chromane and chromene derivatives and uses thereof - Google Patents

Chromane and chromene derivatives and uses thereof Download PDF

Info

Publication number
US7365095B2
US7365095B2 US11/409,467 US40946706A US7365095B2 US 7365095 B2 US7365095 B2 US 7365095B2 US 40946706 A US40946706 A US 40946706A US 7365095 B2 US7365095 B2 US 7365095B2
Authority
US
United States
Prior art keywords
methyl
chromen
dihydro
mmol
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US11/409,467
Other languages
English (en)
Other versions
US20060258714A1 (en
Inventor
Gavin David Heffernan
Gary Paul Stack
Jonathan Laird Gross
Dahui Zhou
Hong Gao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Priority to US11/409,467 priority Critical patent/US7365095B2/en
Assigned to WYETH reassignment WYETH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: HEFFERNAN, GAVIN DAVID, GROSS, JONATHAN LAIRD, ZHOU, DAHUI, GAO, HONG, STACK, GARY PAUL
Publication of US20060258714A1 publication Critical patent/US20060258714A1/en
Priority to US12/051,368 priority patent/US20080182891A1/en
Application granted granted Critical
Publication of US7365095B2 publication Critical patent/US7365095B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/20—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
US11/409,467 2005-04-22 2006-04-21 Chromane and chromene derivatives and uses thereof Expired - Fee Related US7365095B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/409,467 US7365095B2 (en) 2005-04-22 2006-04-21 Chromane and chromene derivatives and uses thereof
US12/051,368 US20080182891A1 (en) 2005-04-22 2008-03-19 Chromane and chromene derivatives and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67382005P 2005-04-22 2005-04-22
US11/409,467 US7365095B2 (en) 2005-04-22 2006-04-21 Chromane and chromene derivatives and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/051,368 Division US20080182891A1 (en) 2005-04-22 2008-03-19 Chromane and chromene derivatives and uses thereof

Publications (2)

Publication Number Publication Date
US20060258714A1 US20060258714A1 (en) 2006-11-16
US7365095B2 true US7365095B2 (en) 2008-04-29

Family

ID=36888961

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/409,467 Expired - Fee Related US7365095B2 (en) 2005-04-22 2006-04-21 Chromane and chromene derivatives and uses thereof
US12/051,368 Abandoned US20080182891A1 (en) 2005-04-22 2008-03-19 Chromane and chromene derivatives and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US12/051,368 Abandoned US20080182891A1 (en) 2005-04-22 2008-03-19 Chromane and chromene derivatives and uses thereof

Country Status (19)

Country Link
US (2) US7365095B2 (US20060258714A1-20061116-C00098.png)
EP (1) EP1874756A1 (US20060258714A1-20061116-C00098.png)
JP (1) JP2008538576A (US20060258714A1-20061116-C00098.png)
KR (1) KR20080008378A (US20060258714A1-20061116-C00098.png)
CN (1) CN101203505A (US20060258714A1-20061116-C00098.png)
AR (1) AR056320A1 (US20060258714A1-20061116-C00098.png)
AU (1) AU2006239937A1 (US20060258714A1-20061116-C00098.png)
BR (1) BRPI0610027A2 (US20060258714A1-20061116-C00098.png)
CA (1) CA2605587A1 (US20060258714A1-20061116-C00098.png)
CO (1) CO6321153A2 (US20060258714A1-20061116-C00098.png)
GT (1) GT200600166A (US20060258714A1-20061116-C00098.png)
IL (1) IL186837A0 (US20060258714A1-20061116-C00098.png)
MX (1) MX2007013163A (US20060258714A1-20061116-C00098.png)
NO (1) NO20075641L (US20060258714A1-20061116-C00098.png)
PE (1) PE20061297A1 (US20060258714A1-20061116-C00098.png)
RU (1) RU2007139541A (US20060258714A1-20061116-C00098.png)
TW (1) TW200716595A (US20060258714A1-20061116-C00098.png)
WO (1) WO2006116165A1 (US20060258714A1-20061116-C00098.png)
ZA (1) ZA200709052B (US20060258714A1-20061116-C00098.png)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080182891A1 (en) * 2005-04-22 2008-07-31 Wyeth Chromane and chromene derivatives and uses thereof
EP2116618A1 (en) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnosis and treatment of Kawasaki disease

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
GT200500296A (es) * 2004-10-21 2006-10-02 Sintesis asimetrica de derivados del dehidrobenzofurano
GT200500297A (es) * 2004-10-21 2006-10-27 Sintesis asimetrica de dehidrobenzofuranos sustituidos
MX2007012883A (es) * 2005-04-22 2007-12-10 Wyeth Corp Derivados de dihidrobenzofurano y usos de los mismos.
EP1871355A1 (en) * 2005-04-22 2008-01-02 Wyeth New therapeutic combianations for the treatment or prevention of depression
EP1871754A1 (en) * 2005-04-22 2008-01-02 Wyeth a Corporation of the State of Delaware Dihydrobenzofuran derivatives and uses thereof
WO2006116151A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
CN101203216A (zh) * 2005-04-22 2008-06-18 惠氏公司 二氢苯并呋喃衍生物及其用途
BRPI0610046A2 (pt) * 2005-04-22 2010-05-25 Wyeth Corp derivados de benzodioxano e benzodioxolano e usos destes
BRPI0610028A2 (pt) * 2005-04-22 2010-05-18 Wyeth Corp combinações terapêuticas para o tratamento ou a prevenção de distúrbios psicóticos
JP2008538578A (ja) * 2005-04-22 2008-10-30 ワイス 疼痛の治療
CN101203217A (zh) * 2005-04-24 2008-06-18 惠氏公司 调节膀胱功能的方法
CL2007000775A1 (es) * 2006-03-24 2008-01-25 Wyeth Corp Uso de compuestos derivados de benzofurano para el tratamiento de un desorden cognitivo.
TW200815388A (en) * 2006-04-18 2008-04-01 Wyeth Corp Chromane and chromene derivatives and uses thereof
WO2007132841A1 (ja) 2006-05-16 2007-11-22 Takeda Pharmaceutical Company Limited 縮合複素環化合物およびその用途
CL2007003043A1 (es) * 2006-10-24 2008-05-30 Wyeth Corp Compuestos derivados de cromano; composicion farmaceutica que los comprende; y uso para el tratamiento de un trastorno psicotico, bipolar, depresivo y ansiedad entre otros.
WO2008052088A1 (en) * 2006-10-25 2008-05-02 Wyeth Chromane derivatives, synthesis thereof, and intermediates thereto
RU2472539C2 (ru) 2007-08-06 2013-01-20 Аллерган, Инк. Способы и устройства для доставки препарата десмопрессина
EP2216023A4 (en) 2007-11-15 2013-03-13 Takeda Pharmaceutical CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF
US8914112B2 (en) 2008-01-23 2014-12-16 Boston Scienctific Neuromodulation Corporation Methods and systems of treating pancreatitis pain caused by sphincter of Oddi dysfunction
US8676322B2 (en) 2008-01-30 2014-03-18 Boston Scientific Neuromodulation Corporation Methods and systems of treating pancreatitis pain
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
PT3085381T (pt) 2008-05-21 2018-05-18 Ferring Bv Desmopressina orodispersível para aumentar o período inicial de sono não perturbado pela noctúria
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
US20120253036A1 (en) 2009-12-11 2012-10-04 Yukinori Nagakura Agent for treating fibromyalgia
CN101921252B (zh) * 2010-07-02 2012-05-09 中国科学院上海有机化学研究所 1-氧杂苯并杂环类化合物、合成方法和用途
RU2549543C2 (ru) 2010-12-21 2015-04-27 Колгейт-Палмолив Компани Галогенированные бифенолы в качестве антибактериальных средств
CN109970533B (zh) * 2012-12-18 2022-06-14 帝斯曼知识产权资产管理有限公司 由(r)-6，10，14-三甲基十五碳-5-烯-2-酮制备的(6r，10r)-6，10，14-三甲基十五烷-2-酮
KR101592560B1 (ko) * 2013-06-21 2016-02-05 제주대학교 산학협력단 신규 플라보노이드 및 그 용도
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
CN107531674B (zh) 2015-02-11 2020-07-31 赛诺维信制药公司 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物
EP3490607A4 (en) 2016-07-29 2020-04-08 Sunovion Pharmaceuticals Inc. COMPOUNDS AND COMPOSITIONS, AND USES THEREOF
CN116514761A (zh) 2016-07-29 2023-08-01 赛诺维信制药公司 化合物、组合物及其用途
SG11202000669VA (en) 2017-08-02 2020-02-27 Sunovion Pharmaceuticals Inc Isochroman compounds and uses thereof
EP3733204A4 (en) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited THERAPEUTIC FOR EXERCISE INCONTINENCE AND STAIR INCONTINENCE
JP2022521208A (ja) * 2019-02-17 2022-04-06 ニューラウェル セラピューティクス うつ病及び他の障害の治療のための組成物及び方法
KR20210139376A (ko) 2019-03-14 2021-11-22 선오비온 파마슈티컬스 인코포레이티드 이소크로마닐 화합물의 염, 및 이의 결정성 형태, 제조방법, 치료 용도 및 약제학적 조성물

Citations (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1262078A (en) 1968-05-24 1972-02-02 Fisons Pharmaceuticals Ltd Preparation of phenoxy fumaric acid compounds and chromone-2-carboxylic acid compounds therefrom
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4654362A (en) 1983-12-05 1987-03-31 Janssen Pharmaceutica, N.V. Derivatives of 2,2'-iminobisethanol
US5089637A (en) 1990-03-21 1992-02-18 Pfizer Inc. Process and intermediates for 2r-benzyl-chroman-6-carbaldehyde
USRE34712E (en) 1988-06-14 1994-08-30 H. Lundbeck A/S Pharmaceutically useful (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroiso benzofuran-5-carbonitrile and non-toxic acid addition salts thereof
US5348976A (en) 1992-09-07 1994-09-20 Kumai Chemical Industry Co., Ltd. Condensed heterocyclic derivatives and agricultural or horticultural fungicides containing the same
DE4430089A1 (de) 1994-08-25 1996-02-29 Bayer Ag Verfahren zur enzymatischen Herstellung von enantiomerenreinen Chroman-2-carbonsäuren und deren Derivaten
US5658796A (en) 1995-06-07 1997-08-19 Seprachem, Inc. Optical resolution of alkyl chroman-2-carboxylates
US5731324A (en) 1993-07-22 1998-03-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
US5767132A (en) 1994-10-14 1998-06-16 Merck Patent Gesellschaft Mit Beschrankter Haftung Pyridyl chroman
US5824682A (en) 1993-08-18 1998-10-20 Janssen Pharmaceutica, N.V. Vasoconstrictive dihydrobenzopyran derivatives
US6083982A (en) 1994-08-15 2000-07-04 Loma Linda University Medical Natriuretic compounds
WO2000058301A1 (fr) 1999-03-30 2000-10-05 Sanofi-Synthelabo Derives de n-[2-(4-aminophenyl)ethyl]-2,3-dihydro-1,4-benzodioxine-2-methanamine, leur preparation et leur application en therapeutique
US6294533B1 (en) * 1998-06-30 2001-09-25 Neuormed Technologies, Inc. Calcium channel blockers
US6310107B1 (en) 1997-02-27 2001-10-30 Takeda Chemical Industries, Ltd. Amine compounds, their production and use as amyloid-β production inhibitors
WO2003029239A1 (en) 2001-10-04 2003-04-10 Wyeth Chroman and benzofuran derivatives as 5-hydroxytryptamine-6 ligands
WO2003029238A1 (en) 2001-10-04 2003-04-10 Wyeth Chroman derivatives as 5-hydroxytryptamine-6 ligands
WO2003031439A1 (en) 2001-10-05 2003-04-17 Wyeth Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1h-indole
US6602903B2 (en) 1997-05-16 2003-08-05 Les Laboratories Servier Substituted heterocyclic compounds
US20040029788A1 (en) 2000-11-01 2004-02-12 Hans-Markus Bender Methods and compositions for the treatment of diseases of the eye
US20040034004A1 (en) 2002-03-08 2004-02-19 Magnus Pfahl Bicyclic heterocycles for the treatment of diabetes and other diseases
US6700001B2 (en) 2001-10-05 2004-03-02 Wyeth Process for stereoselective synthesis of 2-hydroxymethyl chromans
US6716998B2 (en) 2001-10-05 2004-04-06 Wyeth Process for synthesis of 2-yl chroman derivatives
US20040097433A1 (en) 2002-11-15 2004-05-20 Sekhar Boddupalli Chroman derivatives for the reduction of inflammation symptoms
US6747045B2 (en) 1997-12-05 2004-06-08 Janssen Pharmaceutica N.V. (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties
US20040198644A1 (en) 2001-08-01 2004-10-07 Hans-Markus Bender Integrin inhibitors for the treatment of eye diseases
US6812353B2 (en) 2000-09-07 2004-11-02 MERCK Patent Gesellschaft mit beschränkter Haftung Chromanone derivatives
US20050014818A1 (en) 2001-11-09 2005-01-20 Masaru Mitsuda Process for producing optically active chroman derivative and intermediate
US20050065099A1 (en) 2003-09-19 2005-03-24 Gail Walkinshaw Treatment of mitochondrial diseases
WO2005037817A2 (de) 2003-10-16 2005-04-28 Merck Patent Gmbh Verfahren zur herstellung von enantiomerenreinen, in 2-position substituierten chromanderivaten
WO2005044812A1 (en) 2003-10-24 2005-05-19 Wyeth A Corporation Of The State Of Delaware Dihydrobenzofuranyl alkanamine derivatives as 5ht2c agonists
DE102004011265A1 (de) 2004-03-09 2005-09-29 Lutz F. Prof. Dr. Tietze Synthese von Vitamin E
US7045629B2 (en) 2001-04-26 2006-05-16 Merck Patent Gmbh Method for producing-2[-5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane
US20060128689A1 (en) 2004-11-24 2006-06-15 Arthur Gomtsyan Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258176A1 (en) * 1998-02-05 2006-11-16 Asm Japan K.K. Method for forming insulation film
US20050261347A1 (en) * 2003-10-24 2005-11-24 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
US7728155B2 (en) * 2003-10-24 2010-06-01 Wyeth Llc Dihydrobenzofuranyl alkanamines and methods for using same as cns agents
GT200500296A (es) * 2004-10-21 2006-10-02 Sintesis asimetrica de derivados del dehidrobenzofurano
GT200500297A (es) * 2004-10-21 2006-10-27 Sintesis asimetrica de dehidrobenzofuranos sustituidos
EP1871754A1 (en) * 2005-04-22 2008-01-02 Wyeth a Corporation of the State of Delaware Dihydrobenzofuran derivatives and uses thereof
CA2605587A1 (en) * 2005-04-22 2006-11-02 Wyeth Chromane and chromene derivatives and uses thereof
BRPI0610509A2 (pt) * 2005-04-22 2010-06-29 Wyeth Corp tratamento de dependência a drogas
BRPI0610028A2 (pt) * 2005-04-22 2010-05-18 Wyeth Corp combinações terapêuticas para o tratamento ou a prevenção de distúrbios psicóticos
WO2006116151A1 (en) * 2005-04-22 2006-11-02 Wyeth Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
JP2008538578A (ja) * 2005-04-22 2008-10-30 ワイス 疼痛の治療
CN101203216A (zh) * 2005-04-22 2008-06-18 惠氏公司 二氢苯并呋喃衍生物及其用途
EP1871355A1 (en) * 2005-04-22 2008-01-02 Wyeth New therapeutic combianations for the treatment or prevention of depression
CA2603900A1 (en) * 2005-04-22 2006-11-02 Wyeth Crystal forms of {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
BRPI0610046A2 (pt) * 2005-04-22 2010-05-25 Wyeth Corp derivados de benzodioxano e benzodioxolano e usos destes
CN101203217A (zh) * 2005-04-24 2008-06-18 惠氏公司 调节膀胱功能的方法

Patent Citations (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1262078A (en) 1968-05-24 1972-02-02 Fisons Pharmaceuticals Ltd Preparation of phenoxy fumaric acid compounds and chromone-2-carboxylic acid compounds therefrom
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
US4654362A (en) 1983-12-05 1987-03-31 Janssen Pharmaceutica, N.V. Derivatives of 2,2'-iminobisethanol
USRE34712E (en) 1988-06-14 1994-08-30 H. Lundbeck A/S Pharmaceutically useful (+)-1-(3-dimethylaminopropyl)-1-(4'-fluorophenyl)-1,3-dihydroiso benzofuran-5-carbonitrile and non-toxic acid addition salts thereof
US5089637A (en) 1990-03-21 1992-02-18 Pfizer Inc. Process and intermediates for 2r-benzyl-chroman-6-carbaldehyde
US5348976A (en) 1992-09-07 1994-09-20 Kumai Chemical Industry Co., Ltd. Condensed heterocyclic derivatives and agricultural or horticultural fungicides containing the same
US5731324A (en) 1993-07-22 1998-03-24 Eli Lilly And Company Glycoprotein IIb/IIIa antagonists
US5824682A (en) 1993-08-18 1998-10-20 Janssen Pharmaceutica, N.V. Vasoconstrictive dihydrobenzopyran derivatives
US6083982A (en) 1994-08-15 2000-07-04 Loma Linda University Medical Natriuretic compounds
DE4430089A1 (de) 1994-08-25 1996-02-29 Bayer Ag Verfahren zur enzymatischen Herstellung von enantiomerenreinen Chroman-2-carbonsäuren und deren Derivaten
US5767132A (en) 1994-10-14 1998-06-16 Merck Patent Gesellschaft Mit Beschrankter Haftung Pyridyl chroman
US5658796A (en) 1995-06-07 1997-08-19 Seprachem, Inc. Optical resolution of alkyl chroman-2-carboxylates
US6310107B1 (en) 1997-02-27 2001-10-30 Takeda Chemical Industries, Ltd. Amine compounds, their production and use as amyloid-β production inhibitors
US20040077867A1 (en) 1997-02-27 2004-04-22 Kaneyoshi Kato Amine compounds, their production and use
US6602903B2 (en) 1997-05-16 2003-08-05 Les Laboratories Servier Substituted heterocyclic compounds
US6747045B2 (en) 1997-12-05 2004-06-08 Janssen Pharmaceutica N.V. (Benzodioxan, benzofuran or benzopyran) derivatives having fundic relaxation properties
US6294533B1 (en) * 1998-06-30 2001-09-25 Neuormed Technologies, Inc. Calcium channel blockers
WO2000058301A1 (fr) 1999-03-30 2000-10-05 Sanofi-Synthelabo Derives de n-[2-(4-aminophenyl)ethyl]-2,3-dihydro-1,4-benzodioxine-2-methanamine, leur preparation et leur application en therapeutique
US6812353B2 (en) 2000-09-07 2004-11-02 MERCK Patent Gesellschaft mit beschränkter Haftung Chromanone derivatives
US20040029788A1 (en) 2000-11-01 2004-02-12 Hans-Markus Bender Methods and compositions for the treatment of diseases of the eye
US7045629B2 (en) 2001-04-26 2006-05-16 Merck Patent Gmbh Method for producing-2[-5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane
US20040198644A1 (en) 2001-08-01 2004-10-07 Hans-Markus Bender Integrin inhibitors for the treatment of eye diseases
WO2003029238A1 (en) 2001-10-04 2003-04-10 Wyeth Chroman derivatives as 5-hydroxytryptamine-6 ligands
WO2003029239A1 (en) 2001-10-04 2003-04-10 Wyeth Chroman and benzofuran derivatives as 5-hydroxytryptamine-6 ligands
US6716998B2 (en) 2001-10-05 2004-04-06 Wyeth Process for synthesis of 2-yl chroman derivatives
US6700001B2 (en) 2001-10-05 2004-03-02 Wyeth Process for stereoselective synthesis of 2-hydroxymethyl chromans
WO2003031439A1 (en) 2001-10-05 2003-04-17 Wyeth Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1h-indole
US20050014818A1 (en) 2001-11-09 2005-01-20 Masaru Mitsuda Process for producing optically active chroman derivative and intermediate
US20040034004A1 (en) 2002-03-08 2004-02-19 Magnus Pfahl Bicyclic heterocycles for the treatment of diabetes and other diseases
US20040097433A1 (en) 2002-11-15 2004-05-20 Sekhar Boddupalli Chroman derivatives for the reduction of inflammation symptoms
US20050065099A1 (en) 2003-09-19 2005-03-24 Gail Walkinshaw Treatment of mitochondrial diseases
WO2005037817A2 (de) 2003-10-16 2005-04-28 Merck Patent Gmbh Verfahren zur herstellung von enantiomerenreinen, in 2-position substituierten chromanderivaten
WO2005044812A1 (en) 2003-10-24 2005-05-19 Wyeth A Corporation Of The State Of Delaware Dihydrobenzofuranyl alkanamine derivatives as 5ht2c agonists
DE102004011265A1 (de) 2004-03-09 2005-09-29 Lutz F. Prof. Dr. Tietze Synthese von Vitamin E
US20060128689A1 (en) 2004-11-24 2006-06-15 Arthur Gomtsyan Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
Bishop, et al., Expert Opinion Ther. Patent, 13: 1691-1705, 2003.
Cairns, et al., J. Med. Chem., 15: 583, 1972.
Goujon, et al., Journal of the Chemical Society Perkin Trans, 1: 496, 2002.
Gross, Tetrahedron Letters, 44: 8563, 2003.
Gudi, et al., Indian J. Chem., 7: 971, 1969.
Hassan, et al., Brit J. Clin. Pharmacol, 19: 705, 1985.
International Search Report, PCT/US2006/15208.
Office Action mailed Aug. 27, 2007 in U.S. Appl. No. 10/970,714 filed Oct. 21, 2004.
Office Action mailed Jul. 26, 2007 in U.S. Appl. No. 11/409,480 filed Apr. 21, 2006.
Office Action mailed Oct. 17, 2007 in U.S. Appl. No. 10/970,103 filed Oct. 21, 2004.
Office Action mailed Oct. 18, 2007 in U.S. Appl. No. 11/408,909 filed Apr. 21, 2006.
Office Action mailed Oct. 22, 2007 in U.S. Appl. No. 11/409,303 filed Apr. 21, 2006.
Office Action mailed Sep. 19, 2007 in U.S. Appl. No. 11/408,879 filed Apr. 21, 2006.
Office Action mailed Sep. 21, 2007 in U.S. Appl. No. 11/113,170 filed Apr. 22, 2005.
Office Action mailed Sep. 25, 2007 in U.S. Appl. No. 11/409,479 filed Apr. 21, 2006.
Office Action mailed Sep. 28, 2007 in U.S. Appl. No. 11/408,319 filed Apr. 21, 2006.
Ruhemann, J. Chem. Soc., 77: 1121, 1900.
Schaff, et al., J. Med. Chem., 26: 328, 1983.
Snieckus, Chem. Rev., 90: 879, 1990.
Stoermer, et al., Aust. J. Chem., 48:677, 1995.
Witiak, et al., J. Med. Chem., 18: 934, 1975.
Zhang, et al., Tetrahedron Letters, 45: 5229, 2004.

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080182891A1 (en) * 2005-04-22 2008-07-31 Wyeth Chromane and chromene derivatives and uses thereof
EP2116618A1 (en) 2008-05-09 2009-11-11 Agency for Science, Technology And Research Diagnosis and treatment of Kawasaki disease
US20090304680A1 (en) * 2008-05-09 2009-12-10 Agency For Science, Technology And Research (A*Star) Diagnosis and treatment of kawasaki disease

Also Published As

Publication number Publication date
JP2008538576A (ja) 2008-10-30
IL186837A0 (en) 2008-02-09
MX2007013163A (es) 2008-01-21
US20060258714A1 (en) 2006-11-16
EP1874756A1 (en) 2008-01-09
CA2605587A1 (en) 2006-11-02
WO2006116165A1 (en) 2006-11-02
KR20080008378A (ko) 2008-01-23
ZA200709052B (en) 2009-08-26
CN101203505A (zh) 2008-06-18
PE20061297A1 (es) 2006-12-24
GT200600166A (es) 2007-03-14
AU2006239937A1 (en) 2006-11-02
TW200716595A (en) 2007-05-01
BRPI0610027A2 (pt) 2010-05-18
CO6321153A2 (es) 2011-09-20
RU2007139541A (ru) 2009-05-27
NO20075641L (no) 2007-11-20
AR056320A1 (es) 2007-10-03
US20080182891A1 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
US7365095B2 (en) Chromane and chromene derivatives and uses thereof
US7368477B2 (en) Benzofuranyl alkanamine derivatives and uses thereof
US20060241172A1 (en) Benzodioxane and benzodioxolane derivatives and uses thereof
US7402687B2 (en) Dihydrobenzofuran derivatives and uses thereof
US20060258739A1 (en) Dihydrobenzofuran derivatives and uses therof
WO2008052086A1 (en) Benzodioxane derivatives and uses thereof
US20100035871A1 (en) Benzoxazine derivatives and uses thereof
US20100160411A1 (en) Benzoxathiine and benzoxathiole derivatives and uses thereof
WO2008052087A1 (en) Chromane derivatives and uses thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: WYETH, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HEFFERNAN, GAVIN DAVID;STACK, GARY PAUL;GROSS, JONATHAN LAIRD;AND OTHERS;REEL/FRAME:017952/0551;SIGNING DATES FROM 20060613 TO 20060628

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20120429